Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003958 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 702
- Enrollment target
NCT00003958 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 702 participants.
The verdict
NCT00003958, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 702 participants
- Enrollment target
Study Summary
This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.
Interventions
- DRUG cyclophosphamide
- PROCEDURE therapeutic conventional surgery
- RADIATION radiation therapy
- BIOLOGICAL dactinomycin
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 702 participants |
| Start Date | 2002-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003958
The ClinicalTrials.gov registry entry for NCT00003958 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 702 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003958 about?
NCT00003958 is a clinical study titled "Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma". This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use diff...
What is the current status of trial NCT00003958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 702 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00003958?
The interventions under investigation include: cyclophosphamide (DRUG), therapeutic conventional surgery (PROCEDURE), radiation therapy (RADIATION), dactinomycin (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003958?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.